Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

Home
/
update
/
details

10x Genomics Technology Backs Garvan Institute’s TenK10K Project to Revolutionize Complex Disease Treatment

NextEdge Admin

06 Aug 2024

2 min 24 sec

10x Genomics, a leader in single cell and spatial biology, announced its involvement in TenK10K, a large-scale study by the Garvan Institute of Medical Research. TenK10K aims to map 50 million human cells from 10,000 individuals to uncover genomic fingerprints of autoimmune diseases, heart diseases, and cancer. The Garvan Institute selected Chromium GEM-X products from 10x Genomics for single cell data generation to enhance disease risk prediction and treatment response.

Professor Joseph Powell, TenK10K project leader, emphasized the potential of single cell sequencing to reveal unique cell fingerprints, offering new translational opportunities through advanced machine learning methods. The project aims to develop commercial tests for autoimmune diseases, trials for RNA therapies, early treatment targets for cancers and long COVID, and tests to monitor heart attack aftermath and sudden death risks.

Chromium GEM-X products, known for their increased sensitivity, throughput, and data quality, will be used in the study. Ben Hindson, Co-Founder and Chief Scientific Officer at 10x Genomics, highlighted the potential impact of large-scale single cell analysis on understanding, diagnosing, and treating diseases. The project builds on the Garvan Institute's OneK1K study, which analyzed over one million cells from 1,000 people and led to a clinical trial in Sydney hospitals to match patients with effective treatments.

In partnership with Illumina, the Garvan Institute will receive supplies, equipment, and research support. 10x Genomics continues to drive innovation in single cell and spatial biology, supporting breakthroughs in oncology, immunology, neuroscience, and more.